Is erlotinib really active after failure of gefitinib in advanced non-small-cell lung cancer patients?

Annals of Oncology

Volumn 20, Issue 4, 2009, Pages 790-791

  Vasile, E ^a   Tibaldi, C ^a   Falcone, A ^a,b  

^a Ospedale Civile   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; SCATTER FACTOR RECEPTOR;

ARTICLE; CANCER CONTROL; DRUG ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; DRUG TREATMENT FAILURE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MOLECULAR MECHANICS; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; QUINAZOLINES; SALVAGE THERAPY;

EID: 63549138664     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp013     Document Type: Article

References (14)

1. Lee DH, Kim SW, Suh C et al. Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment. Ann Oncol 2008; 19: 2039-2042.
2. Cho BC, Im CK, Park MS et al. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol 2007; 25: 2528-2533.
3. Costa DB, Nguyen KSH, Cho BC et al. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res 2008; 14: 7060-7067.
4. Wong AS, Song R, Bee-Kee Seah S et al. Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer. J Thorac Oncol 2008; 3: 400-404.
5. Vasile E, Tibaldi C, Chella A, Falcone A. Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib. J Thorac Oncol 2008; 3: 912-914.
6. Viswanathan A, Pillot G, Govindan R. Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer 2005; 50: 417-418.
7. Gridelli C, Maione P, Galetta D et al. Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer. J Thorac Oncol 2007; 2: 758-761.
8. Garfield DH. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma. J Clin Oncol 2005; 23: 7738-7740.
9. Chang JWC, Chou CL, Huang SF et al. Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer. Lung Cancer 2007; 58: 414-417.
10. Sim SH, Han SW, Oh SY et al. Erlotinib treatment after progression on gefitinib in non-small cell lung cancer (NSCLC). J Thorac Oncol 2007; 8: S739 P3-P140.
11. Shih YN, Liou JL, Jiang WC et al. Phase II study of erlotinib in patients with advanced non-small cell lung cancer who failed prior gefitinib treatment. J Thorac Oncol 2007; 8: S743; P3-P150.
12. Kim H, Kim Y, Oh S et al. Response to erlotinib after failure of gefitinib in non-small cell lung cancer with EGFR mutation. J Clin Oncol 2008; 26: (Abstr 19072).
13. Kobayashi S, Boggon TJ, Dayaram T et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786-792.
14. Engelman JA, Zejnullahu K, Mitsudomi T et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039-1043.